JP2023530120A - 血管性認知症を治療するためのＲｈｏキナーゼ阻害剤の使用方法 - Google Patents

血管性認知症を治療するためのＲｈｏキナーゼ阻害剤の使用方法 Download PDF

Info

Publication number
JP2023530120A
JP2023530120A JP2022576866A JP2022576866A JP2023530120A JP 2023530120 A JP2023530120 A JP 2023530120A JP 2022576866 A JP2022576866 A JP 2022576866A JP 2022576866 A JP2022576866 A JP 2022576866A JP 2023530120 A JP2023530120 A JP 2023530120A
Authority
JP
Japan
Prior art keywords
patient
fasudil
dementia
vascular dementia
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022576866A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023530120A5 (https=
Inventor
マカリスター，トーマス
ジェイコブソン，スヴェン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Woolsey Pharmaceuticals Inc
Original Assignee
Woolsey Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Woolsey Pharmaceuticals Inc filed Critical Woolsey Pharmaceuticals Inc
Publication of JP2023530120A publication Critical patent/JP2023530120A/ja
Publication of JP2023530120A5 publication Critical patent/JP2023530120A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022576866A 2020-06-15 2021-01-08 血管性認知症を治療するためのＲｈｏキナーゼ阻害剤の使用方法 Pending JP2023530120A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063039141P 2020-06-15 2020-06-15
US63/039,141 2020-06-15
US202063046173P 2020-06-30 2020-06-30
US63/046,173 2020-06-30
PCT/US2021/012590 WO2021257122A1 (en) 2020-06-15 2021-01-08 Methods of using rho kinase inhibitors to treat vascular dementia

Publications (2)

Publication Number Publication Date
JP2023530120A true JP2023530120A (ja) 2023-07-13
JP2023530120A5 JP2023530120A5 (https=) 2024-01-15

Family

ID=79268240

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022576866A Pending JP2023530120A (ja) 2020-06-15 2021-01-08 血管性認知症を治療するためのＲｈｏキナーゼ阻害剤の使用方法

Country Status (7)

Country Link
US (1) US20230285409A1 (https=)
EP (1) EP4164652A4 (https=)
JP (1) JP2023530120A (https=)
CN (1) CN116249532A (https=)
CA (1) CA3180411A1 (https=)
MX (1) MX2022015800A (https=)
WO (1) WO2021257122A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240423998A1 (en) 2021-11-29 2024-12-26 Woolsey Pharmaceuticals, Inc. Methods of treating agitation and other dementia-associated behavioral symptoms
WO2024243197A2 (en) * 2023-05-24 2024-11-28 Woolsey Pharmaceuticals, Inc. Method of treating patients with notch3 mutations
WO2025024104A2 (en) * 2023-07-06 2025-01-30 Woolsey Pharmaceuticals, Inc. Method for reducing caregiver burden associated with alzheimer's disease
WO2025101834A1 (en) * 2023-11-10 2025-05-15 Woolsey Pharmaceuticals, Inc. Methods of treating sporadic cerebral small vessel disease
CN119954776A (zh) * 2025-03-03 2025-05-09 中国药科大学 一种法舒地尔二氯乙酸盐的制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080108568A1 (en) * 2006-08-10 2008-05-08 Tgen Compounds for improving learning and memory

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005117896A1 (de) * 2004-06-03 2005-12-15 Schering Aktiengesellschaft Formulierungen, die fasudil, eine matrix und einem mantel enthalten
US8648069B2 (en) * 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
EP2285217A4 (en) * 2008-05-12 2011-06-08 Amnestix Inc CONNECTIONS TO IMPROVE LEARNING AND MEMORY
RU2014104690A (ru) * 2011-08-12 2015-09-20 Е.Р.Д.Е.-ААК-Диагностик ГмбХ АГОНИСТИЧЕСКИЕ АУТОАНТИТЕЛА К α1- И β2-АДРЕНЕРГИЧЕСКИМ РЕЦЕПТОРАМ ПРИ БОЛЕЗНИ АЛЬЦГЕЙМЕРА И СОСУДИСТОЙ ДЕМЕНЦИИ
WO2013066151A1 (en) * 2011-10-31 2013-05-10 N.V. Nutricia Improving recognition
US20150297679A1 (en) * 2012-12-14 2015-10-22 The Brigham And Women's Hospital, Inc. Methods and assays relating to macrophage differentiation
MX2022008513A (es) * 2020-01-09 2022-08-08 Woolsey Pharmaceuticals Inc Metodos para tratar la deambulacion asociada con la demencia cortical.
US20230080958A1 (en) * 2020-02-10 2023-03-16 Woolsey Pharmaceuticals, Inc. Methods of treating pseudobulbar affect and other emotional disturbances

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080108568A1 (en) * 2006-08-10 2008-05-08 Tgen Compounds for improving learning and memory

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CLIN NEUROPHARMACOL, vol. 19, no. 5, JPN6025006296, 1996, pages 428 - 438, ISSN: 0005672017 *
HERALD OF MEDICINE, vol. 31, no. 11, JPN6025006297, 2012, pages 1438 - 1440, ISSN: 0005672018 *
神経治療学, vol. 13, no. 1, JPN6025006295, 1996, pages 43 - 50, ISSN: 0005672016 *

Also Published As

Publication number Publication date
US20230285409A1 (en) 2023-09-14
CN116249532A (zh) 2023-06-09
CA3180411A1 (en) 2021-12-23
WO2021257122A1 (en) 2021-12-23
EP4164652A4 (en) 2024-07-10
EP4164652A1 (en) 2023-04-19
MX2022015800A (es) 2023-01-24

Similar Documents

Publication Publication Date Title
JP2023530120A (ja) 血管性認知症を治療するためのＲｈｏキナーゼ阻害剤の使用方法
US11642352B2 (en) Methods of treating wandering in Lewy dody dementia
US11771704B1 (en) Methods of using rho kinase inhibitors to treat alzheimer's disease
US11666583B2 (en) Methods of treating cortical dementia associated wandering
US11311553B1 (en) Methods of treating 4-repeat tauopathies
US20230263806A1 (en) Methods of treating proteinopathies
US20230405017A1 (en) Methods of using rho kinase inhibitors to treat frontotemporal dementia
EP4203960A1 (en) Methods of treating age-related cognitive decline
WO2022046160A1 (en) Methods of treating age-related cognitive decline

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231227

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250516

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250826

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251029

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260324